Tag: #oncology

Pfizer’s BRAFTOVI Combo Shows Longer Progression-Free Survival in First-Line BRAF V600E Metastatic Colorectal Cancer

Phase 3 BREAKWATER Cohort 3 data show encorafenib plus cetuximab with FOLFIRI extended median PFS to 15.2 months vs. 8.3 months in control.

$PFE, #oncology, #colorectalcancer, #pfizer, #braftovi

FDA Approves Lifyorli Combo for Platinum-Resistant Ovarian Cancer, Showing Survival Gain

FDA clears Corcept’s Lifyorli with nab-paclitaxel for platinum-resistant ovarian-type cancers, the first cortisol-receptor blocker to extend survival.

#ovariancancer, #fda, #chemotherapy, #drugapproval, #oncology